FY2024 EPS Forecast for LENZ Therapeutics Boosted by Analyst

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Research analysts at HC Wainwright boosted their FY2024 earnings per share estimates for shares of LENZ Therapeutics in a report issued on Thursday, November 7th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($2.01) for the year, up from their previous forecast of ($2.54). HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for LENZ Therapeutics’ Q4 2024 earnings at ($0.43) EPS, FY2025 earnings at ($2.13) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($0.55) EPS and FY2028 earnings at $0.55 EPS.

Several other research analysts also recently commented on the company. Piper Sandler restated an “overweight” rating and issued a $36.00 target price on shares of LENZ Therapeutics in a research note on Thursday, August 15th. Raymond James initiated coverage on LENZ Therapeutics in a research report on Friday, September 27th. They set an “outperform” rating and a $37.00 price target for the company. Finally, William Blair upgraded LENZ Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, LENZ Therapeutics presently has an average rating of “Buy” and an average price target of $35.40.

LENZ Therapeutics Stock Performance

Shares of NASDAQ LENZ opened at $37.25 on Monday. LENZ Therapeutics has a 52 week low of $14.07 and a 52 week high of $37.51. The business has a 50-day simple moving average of $25.18 and a two-hundred day simple moving average of $21.42.

LENZ Therapeutics (NASDAQ:LENZ) last issued its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.09. During the same period in the prior year, the company posted ($1.33) earnings per share.

Institutional Trading of LENZ Therapeutics

Large investors have recently modified their holdings of the business. American International Group Inc. bought a new stake in shares of LENZ Therapeutics during the 1st quarter valued at about $44,000. SG Americas Securities LLC purchased a new position in shares of LENZ Therapeutics during the 3rd quarter valued at about $107,000. Squarepoint Ops LLC purchased a new position in shares of LENZ Therapeutics during the 2nd quarter valued at about $181,000. GSA Capital Partners LLP purchased a new position in shares of LENZ Therapeutics during the 3rd quarter valued at about $246,000. Finally, Rhumbline Advisers raised its holdings in shares of LENZ Therapeutics by 265.6% during the 2nd quarter. Rhumbline Advisers now owns 16,812 shares of the company’s stock valued at $291,000 after buying an additional 12,214 shares in the last quarter. Institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.